Hodges Capital Management Inc. Sells 41,409 Shares of Halozyme Therapeutics, Inc. $HALO

Hodges Capital Management Inc. reduced its position in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 21.4% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 152,156 shares of the biopharmaceutical company’s stock after selling 41,409 shares during the period. Hodges Capital Management Inc. owned 0.12% of Halozyme Therapeutics worth $7,915,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Wealth Preservation Advisors LLC purchased a new stake in Halozyme Therapeutics in the 1st quarter valued at about $32,000. SVB Wealth LLC purchased a new stake in shares of Halozyme Therapeutics during the first quarter valued at approximately $33,000. Brooklyn Investment Group increased its position in shares of Halozyme Therapeutics by 1,558.1% during the first quarter. Brooklyn Investment Group now owns 713 shares of the biopharmaceutical company’s stock valued at $45,000 after acquiring an additional 670 shares during the last quarter. CWM LLC lifted its holdings in Halozyme Therapeutics by 46.3% during the first quarter. CWM LLC now owns 1,383 shares of the biopharmaceutical company’s stock worth $88,000 after acquiring an additional 438 shares during the period. Finally, Harvest Fund Management Co. Ltd purchased a new position in Halozyme Therapeutics in the first quarter worth $89,000. 97.79% of the stock is currently owned by hedge funds and other institutional investors.

Halozyme Therapeutics Stock Performance

NASDAQ HALO opened at $68.24 on Monday. The firm has a market cap of $8.02 billion, a P/E ratio of 15.62, a price-to-earnings-growth ratio of 0.35 and a beta of 1.18. The company has a quick ratio of 7.01, a current ratio of 8.36 and a debt-to-equity ratio of 4.54. The company’s 50 day moving average is $70.66 and its 200-day moving average is $62.89. Halozyme Therapeutics, Inc. has a 12-month low of $42.01 and a 12-month high of $79.50.

Halozyme Therapeutics (NASDAQ:HALO) last released its quarterly earnings data on Monday, November 3rd. The biopharmaceutical company reported $1.72 earnings per share for the quarter, beating analysts’ consensus estimates of $1.63 by $0.09. Halozyme Therapeutics had a net margin of 47.28% and a return on equity of 150.85%. The business had revenue of $354.26 million during the quarter, compared to analyst estimates of $339.18 million. During the same period in the previous year, the business earned $1.27 EPS. Halozyme Therapeutics’s revenue was up 22.1% compared to the same quarter last year. Sell-side analysts predict that Halozyme Therapeutics, Inc. will post 4.73 earnings per share for the current year.

Wall Street Analysts Forecast Growth

HALO has been the subject of several research analyst reports. Leerink Partnrs raised Halozyme Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Tuesday, October 14th. Benchmark raised their price objective on shares of Halozyme Therapeutics from $75.00 to $90.00 and gave the stock a “buy” rating in a report on Wednesday, September 24th. Wall Street Zen cut shares of Halozyme Therapeutics from a “strong-buy” rating to a “buy” rating in a research note on Saturday. HC Wainwright restated a “buy” rating on shares of Halozyme Therapeutics in a research note on Tuesday, October 21st. Finally, Weiss Ratings raised shares of Halozyme Therapeutics from a “hold (c+)” rating to a “buy (b)” rating in a report on Friday. Seven analysts have rated the stock with a Buy rating and seven have issued a Hold rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $75.00.

Insider Activity

In related news, CEO Helen Torley sold 20,000 shares of the business’s stock in a transaction on Wednesday, October 1st. The stock was sold at an average price of $75.35, for a total transaction of $1,507,000.00. Following the sale, the chief executive officer directly owned 733,719 shares in the company, valued at approximately $55,285,726.65. The trade was a 2.65% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CFO Nicole Labrosse sold 20,000 shares of the firm’s stock in a transaction dated Wednesday, September 10th. The stock was sold at an average price of $75.71, for a total value of $1,514,200.00. Following the completion of the transaction, the chief financial officer owned 24,306 shares of the company’s stock, valued at approximately $1,840,207.26. This represents a 45.14% decrease in their position. The SEC filing for this sale provides additional information. Over the last three months, insiders sold 108,227 shares of company stock worth $7,779,595. 2.40% of the stock is owned by corporate insiders.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.